Currently, I am studying the acceptability, preferences and feasibility of monoclonal antibodies for post-discharge malaria chemoprevention (PDMC) in under-five children in three sub-Saharan Africa countries. This involves a  comparative qualitative assessment of mAbs against the available PDMC options (pills and vaccines); a choice experiment for preferences and willingness to pay; and a health system assessment of feasibility of implementation.